Galena Biopharma Price Target Raised to $6.00 at Maxim Group (GALE)

Galena Biopharma (NASDAQ: GALE) had its price target lifted by Maxim Group from $5.00 to $6.00 in a research report sent to investors on Tuesday morning. The firm currently has a buy rating on the stock.

A number of other firms have also recently commented on GALE. Analysts at Zacks reiterated an outperform rating on shares of Galena Biopharma in a research note to investors on Friday, February 8th. They now have a $4.00 price target on the stock. Analysts at Piper Jaffray initiated coverage on shares of Galena Biopharma in a research note to investors on Monday, December 31st. They set an overweight rating and a $2.50 price target on the stock.

Eight analysts have rated the stock with a buy rating, Galena Biopharma has a consensus rating of Buy and a consensus price target of $4.69.

Shares of Galena Biopharma (NASDAQ: GALE) opened at 1.94 on Tuesday. Galena Biopharma has a one year low of $1.04 and a one year high of $3.54. The stock’s 50-day moving average is currently $1.90. The company’s market cap is $134.8 million.

Galena Biopharma, Inc. (NASDAQ: GALE), formerly RXi Pharmaceuticals Corporation, is a biotechnology company focused on discovering, developing and commercializing therapies addressing unmet medical needs using RNAi-targeted and immunotherapy technologies.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.